Clinical Trials Logo
  1. Home
  2. Phelan-McDermid Syndrome
  3. NCT05025241

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) — PMS-001  

Phelan-McDermid Syndrome Clinical Trial

Official title:
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)

Clinical Trial Summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Phelan-McDermid Syndrome.

Clinical Trial Description

The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Phelan-McDermid Syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment with NNZ-2591 oral solution (50 mg/mL) doses for a total of 13 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05025241
Study type Interventional
Source Neuren Pharmaceuticals Limited
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 8, 2022
Completion date December 31, 2023
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT03493607 - AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy Phase 2
Completed NCT03426059 - Mapping the Phenotype in Adults With Phelan-McDermid Syndrome
Recruiting NCT02461420 - Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
Completed NCT02000167 - Mitochondrial Dysfunction in Phelan-McDermid Syndrome
Enrolling by invitation NCT04312152 - Q10 Ubiquinol in Autism Spectrum Disorder and in Phelan-McDermid Syndrome. N/A
Completed NCT05105685 - Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS Phase 1/Phase 2
Enrolling by invitation NCT05187377 - A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism Phase 2
Completed NCT01525901 - Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome) Phase 2
Completed NCT02710084 - Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome Phase 2